CA2873278C - Method for quantifying immune cells in tumoral tissues and its applications - Google Patents

Method for quantifying immune cells in tumoral tissues and its applications Download PDF

Info

Publication number
CA2873278C
CA2873278C CA2873278A CA2873278A CA2873278C CA 2873278 C CA2873278 C CA 2873278C CA 2873278 A CA2873278 A CA 2873278A CA 2873278 A CA2873278 A CA 2873278A CA 2873278 C CA2873278 C CA 2873278C
Authority
CA
Canada
Prior art keywords
cells
tumour
stained
density
stained cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2873278A
Other languages
English (en)
French (fr)
Other versions
CA2873278A1 (en
Inventor
Jerome Galon
Franck Pages
Bernhard Mlecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Cité
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Universite de Paris filed Critical Assistance Publique - Hôpitaux de Paris
Publication of CA2873278A1 publication Critical patent/CA2873278A1/en
Application granted granted Critical
Publication of CA2873278C publication Critical patent/CA2873278C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2873278A 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications Active CA2873278C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2012/001446 2012-06-14
IB2012001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (2)

Publication Number Publication Date
CA2873278A1 CA2873278A1 (en) 2013-12-19
CA2873278C true CA2873278C (en) 2021-10-26

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2873278A Active CA2873278C (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Country Status (13)

Country Link
US (1) US10317408B2 (cg-RX-API-DMAC10.html)
EP (1) EP2861986B1 (cg-RX-API-DMAC10.html)
JP (1) JP6449765B2 (cg-RX-API-DMAC10.html)
KR (1) KR102179848B1 (cg-RX-API-DMAC10.html)
CN (1) CN104541167B (cg-RX-API-DMAC10.html)
AU (1) AU2013276470B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014031143B8 (cg-RX-API-DMAC10.html)
CA (1) CA2873278C (cg-RX-API-DMAC10.html)
DE (1) DE13731071T1 (cg-RX-API-DMAC10.html)
ES (1) ES2902879T3 (cg-RX-API-DMAC10.html)
IL (1) IL235738B (cg-RX-API-DMAC10.html)
SG (1) SG11201408107RA (cg-RX-API-DMAC10.html)
WO (1) WO2013186374A1 (cg-RX-API-DMAC10.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6605506B2 (ja) 2014-02-24 2019-11-13 ヴェンタナ メディカル システムズ， インク． ＣＤ３、ＣＤ８、ＣＤ２０及びＦｏｘＰ３の同時検出によりがんに対する免疫応答をスコア化するための方法、キット、及びシステム
JP6802153B2 (ja) * 2014-09-03 2020-12-16 ヴェンタナ メディカル システムズ， インク． 免疫スコアを計算するためのシステム及び方法
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
US10034901B2 (en) 2015-01-22 2018-07-31 University Of Massachusetts Cancer immunotherapy
CN113671186A (zh) * 2015-10-23 2021-11-19 诺华股份有限公司 对包含肿瘤组织的样品评分的方法
JP7281903B2 (ja) * 2016-05-09 2023-05-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 固形腫瘍を有する患者をクラス分けするための方法
EP3459046B1 (en) * 2016-05-18 2021-06-16 F. Hoffmann-La Roche AG Tumor proximity measure
WO2018027223A1 (en) * 2016-08-05 2018-02-08 Duke University Camkk2 inhibitor compositions and methods of using the same
EP3532984B1 (en) * 2016-10-27 2024-05-08 Koninklijke Philips N.V. Apparatus for determining cellular composition information in one or more tissue samples
WO2018081817A2 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
WO2019020556A1 (en) * 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. METHODS AND SYSTEMS FOR ASSESSING INFILTRAT OF IMMUNE CELLS IN TUMOR SAMPLES
CA3089562A1 (en) 2018-01-30 2019-08-08 University Of Massachusetts Methods of treating a wound using epigenetic regulation
WO2019149817A1 (en) 2018-01-31 2019-08-08 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iii colorectal cancer
WO2020161125A1 (en) * 2019-02-05 2020-08-13 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in stage iv colorectal cancer
CN114072676B (zh) 2019-06-03 2024-07-12 法国国家卫生及研究医学协会 调节治疗方案的方法
WO2021092071A1 (en) 2019-11-07 2021-05-14 Oncxerna Therapeutics, Inc. Classification of tumor microenvironments
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
JP7741831B2 (ja) * 2020-06-30 2025-09-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 術前補助療法及び根治手術後の固形がんを患っている患者の再発及び／又は死亡のリスクを予測するための方法
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
WO2023018085A1 (ko) * 2021-08-10 2023-02-16 주식회사 루닛 병리 슬라이드 이미지와 관련된 정보를 출력하는 방법 및 장치
CN114494155B (zh) * 2021-12-31 2026-07-28 广东省人民医院 非小细胞肺癌ihc染色图像肿瘤区域免疫分级方法、系统及存储介质
US20250035635A1 (en) 2022-03-17 2025-01-30 Institut National De La Sante Et De La Recherche Medicale Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
US12700249B2 (en) * 2023-07-06 2026-08-04 Pictor Labs, Inc. Systems and methods for training machine learning on noisy and inaccurate immunostains
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020198A2 (en) * 1995-11-30 1997-06-05 Chromavision Medical Systems, Inc. Method and apparatus for automated image analysis of biological specimens
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
JP4933563B2 (ja) * 2005-12-19 2012-05-16 ヴェンタナ メディカル システムズ， インコーポレイテッド 解剖病理学における自動リーンメソッド
CN102165489B (zh) * 2008-09-16 2015-11-25 赫斯托克斯公司 生物标志物表达的可再现量化
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Also Published As

Publication number Publication date
JP2015525349A (ja) 2015-09-03
CN104541167A (zh) 2015-04-22
CA2873278A1 (en) 2013-12-19
ES2902879T3 (es) 2022-03-30
JP6449765B2 (ja) 2019-01-09
CN104541167B (zh) 2018-05-01
BR112014031143B1 (pt) 2022-03-03
EP2861986A1 (en) 2015-04-22
IL235738B (en) 2019-02-28
KR102179848B1 (ko) 2020-11-17
SG11201408107RA (en) 2015-01-29
WO2013186374A1 (en) 2013-12-19
AU2013276470A1 (en) 2014-11-27
KR20150023760A (ko) 2015-03-05
EP2861986B1 (en) 2021-11-10
IL235738A0 (en) 2015-01-29
US10317408B2 (en) 2019-06-11
DE13731071T1 (de) 2016-08-18
BR112014031143B8 (pt) 2022-11-22
US20150153349A1 (en) 2015-06-04
AU2013276470B2 (en) 2018-06-07
BR112014031143A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
US10317408B2 (en) Method for quantifying immune cells in tumoral tissues and its applications
Bilous et al. Current perspectives on HER2 testing: a review of national testing guidelines
KR102502745B1 (ko) 고형종양 진단을 위한 바이오마커 절대 정량 방법 및 장치
JP6405319B2 (ja) 乳癌予知のための画像分析
Lloyd et al. Using image analysis as a tool for assessment of prognostic and predictive biomarkers for breast cancer: How reliable is it?
EP3117259B1 (en) Assessment of staining quality
US20110111435A1 (en) Detecting Cell Surface Markers
JP5866362B2 (ja) 画像解析による固形腫瘍進行の予後検査
US20240310379A1 (en) A method for measuring a prognostic marker in prostate cancer or in breast cancer
Brügmann et al. Testing HER2 in breast cancer: a comparative study on BRISH, FISH, and IHC
Liu et al. A comparative performance analysis of multispectral and rgb imaging on her2 status evaluation for the prediction of breast cancer prognosis
Wang et al. Laboratory validation studies in Ki-67 digital image analysis of breast carcinoma: a pathway to routine quality assurance
CN115602313A (zh) 用于疾病疗效与生存预后预测的生物标志物及其用途
Pinder et al. HER2 testing in the UK: further update to
Maresh et al. Development and Application of Tissue Microarrays for Biomarker Studies
Holten-Rossing Digitalization in pathology

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251009

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804